Blacksmith Medicines

Blacksmith Medicines is a private, preclinical-stage biotech focused on a novel drug discovery platform targeting metalloenzymes, which represent over 30% of all enzymes and are implicated in a wide range of diseases. The company's proprietary platform integrates a focused fragment library of metal-binding pharmacophores, a comprehensive metalloenzyme database, a metallo-CRISPR library for target validation, and computational modeling. Led by a team with deep expertise in bioinorganic chemistry and biotech operations, Blacksmith is positioned to pursue historically challenging targets in oncology and beyond, though it faces the inherent risks of early-stage platform validation and target discovery.

Integrated platform for metalloenzyme drug discovery featuring a focused fragment library of metal-binding pharmacophores (MBPs), a comprehensive metalloenzyme database, a custom metallo-CRISPR library for target validation, and specialized computational modeling.

Direct competition is limited but growing, with a few biotechs (e.g., sister company Forge Therapeutics) and academic groups exploring metalloenzyme inhibition. Indirect competition comes from all modalities targeting the same disease pathways. Blacksmith's differentiation lies in its specialized, integrated platform and deep expertise in medicinal bioinorganic chemistry.